Ptc Therapeutics Inc.

Plus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more

Seven new products get positive opinions in April

At nearly $1.7B, Zealand got $300M more than the prior top cash payment

How the once-dominant cancer company has overhauled its strategy for long-term growth

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months

BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025

Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer

Plus: KCC2 activation nears inflection point

But partnership lands fourth on overall upfront payment